77 related articles for article (PubMed ID: 17009030)
1. Dihydrodiol dehydrogenase in drug resistance and sensitivity of human carcinomas.
Pan BF; Nelson JA
Cancer Chemother Pharmacol; 2007 Apr; 59(5):697-702. PubMed ID: 17009030
[TBL] [Abstract][Full Text] [Related]
2. Ubiquitous induction of resistance to platinum drugs in human ovarian, cervical, germ-cell and lung carcinoma tumor cells overexpressing isoforms 1 and 2 of dihydrodiol dehydrogenase.
Deng HB; Adikari M; Parekh HK; Simpkins H
Cancer Chemother Pharmacol; 2004 Oct; 54(4):301-7. PubMed ID: 15138708
[TBL] [Abstract][Full Text] [Related]
3. Induction of apoptosis in human renal cell carcinoma cells by vitamin E succinate in caspase-independent manner.
Wu XX; Kakehi Y; Jin XH; Inui M; Sugimoto M
Urology; 2009 Jan; 73(1):193-9. PubMed ID: 18692875
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of lexatumumab-induced apoptosis in human solid cancer cells by Cisplatin in caspase-dependent manner.
Wu XX; Kakehi Y
Clin Cancer Res; 2009 Mar; 15(6):2039-47. PubMed ID: 19276256
[TBL] [Abstract][Full Text] [Related]
5. FTY720 induced Bcl-associated and Fas-independent apoptosis in human renal cancer cells in vitro and significantly reduced in vivo tumor growth in mouse xenograft.
Ubai T; Azuma H; Kotake Y; Inamoto T; Takahara K; Ito Y; Kiyama S; Sakamoto T; Horie S; Muto S; Takahara S; Otsuki Y; Katsuoka Y
Anticancer Res; 2007; 27(1A):75-88. PubMed ID: 17352219
[TBL] [Abstract][Full Text] [Related]
6. Characterization of cell death events induced by anti-neoplastic drugs cisplatin, paclitaxel and 5-fluorouracil on human hepatoma cell lines: Possible mechanisms of cell resistance.
Brenes O; Arce F; Gätjens-Boniche O; Díaz C
Biomed Pharmacother; 2007 Jul; 61(6):347-55. PubMed ID: 17399942
[TBL] [Abstract][Full Text] [Related]
7. Human renal UOK130 tumor cells: a drug resistant cell line with highly selective over-expression of glutathione S-transferase-pi isozyme.
Wang W; Liu G; Zheng J
Eur J Pharmacol; 2007 Jul; 568(1-3):61-7. PubMed ID: 17509556
[TBL] [Abstract][Full Text] [Related]
8. Indomethacin induces apoptosis in 786-O renal cell carcinoma cells by activating mitogen-activated protein kinases and AKT.
Ou YC; Yang CR; Cheng CL; Raung SL; Hung YY; Chen CJ
Eur J Pharmacol; 2007 Jun; 563(1-3):49-60. PubMed ID: 17341418
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effects of an imidazoquinoline in renal cell carcinoma.
Schwartz MJ; Liu H; Hwang DH; Kawamoto H; Scherr DS
Urology; 2009 May; 73(5):1156-62. PubMed ID: 19118885
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of death receptor 4 mediated apoptosis and cytotoxicity in renal cell carcinoma cells by subtoxic concentrations of doxorubicin.
Jin X; Wu XX; Abdel-Muneem Nouh MA; Kakehi Y
J Urol; 2007 May; 177(5):1894-9. PubMed ID: 17437844
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity of renal cell carcinoma to aminoflavone: role of CYP1A1.
Loaiza-Pérez AI; Kenney S; Boswell J; Hollingshead M; Hose C; Linehan WM; Worrell R; Rubinstein L; Sausville EA; Vistica DT
J Urol; 2004 Apr; 171(4):1688-97. PubMed ID: 15017268
[TBL] [Abstract][Full Text] [Related]
12. Zoledronic acid induces caspase-dependent apoptosis in renal cancer cell lines.
Ullen A; Schwarz S; Lennartsson L; Kalkner KM; Sandstrom P; Costa F; Lennernas B; Linder S; Nilsson S
Scand J Urol Nephrol; 2009; 43(2):98-103. PubMed ID: 19101859
[TBL] [Abstract][Full Text] [Related]
13. The altered apoptotic pathways in cisplatin and etoposide-resistant melanoma cells are drug specific.
Kissel CK; Schadendorf D; Röckmann H
Melanoma Res; 2006 Dec; 16(6):527-35. PubMed ID: 17119454
[TBL] [Abstract][Full Text] [Related]
14. Resistance to the tubulin-binding agents in renal cell carcinoma: no mutations in the class I beta-tubulin gene but changes in tubulin isotype protein expression.
Ferguson RE; Taylor C; Stanley A; Butler E; Joyce A; Harnden P; Patel PM; Selby PJ; Banks RE
Clin Cancer Res; 2005 May; 11(9):3439-45. PubMed ID: 15867246
[TBL] [Abstract][Full Text] [Related]
15. Connexin 32 potentiates vinblastine-induced cytotoxicity in renal cell carcinoma cells.
Sato H; Senba H; Virgona N; Fukumoto K; Ishida T; Hagiwara H; Negishi E; Ueno K; Yamasaki H; Yano T
Mol Carcinog; 2007 Mar; 46(3):215-24. PubMed ID: 17186540
[TBL] [Abstract][Full Text] [Related]
16. Resistance to Fas-mediated apoptosis in malignant tumours is rescued by KN-93 and cisplatin via downregulation of c-FLIP expression and phosphorylation.
Yang BF; Xiao C; Li H; Yang SJ
Clin Exp Pharmacol Physiol; 2007 Dec; 34(12):1245-51. PubMed ID: 17973862
[TBL] [Abstract][Full Text] [Related]
17. Invasive ability of human renal cell carcinoma cell line Caki-2 is accelerated by gamma-aminobutyric acid, via sustained activation of ERK1/2 inducible matrix metalloproteinases.
Inamoto T; Azuma H; Sakamoto T; Kiyama S; Ubai T; Kotake Y; Watanabe M; Katsuoka Y
Cancer Invest; 2007 Oct; 25(7):574-83. PubMed ID: 18027151
[TBL] [Abstract][Full Text] [Related]
18. Association of caspase-8 mutation with chemoresistance to cisplatin in HOC313 head and neck squamous cell carcinoma cells.
Liu J; Uematsu H; Tsuchida N; Ikeda MA
Biochem Biophys Res Commun; 2009 Dec; 390(3):989-94. PubMed ID: 19852930
[TBL] [Abstract][Full Text] [Related]
19. In vivo validation of PAX2 as a target for renal cancer therapy.
Hueber PA; Iglesias D; Chu LL; Eccles M; Goodyer P
Cancer Lett; 2008 Jun; 265(1):148-55. PubMed ID: 18439754
[TBL] [Abstract][Full Text] [Related]
20. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
